Literature DB >> 28381537

Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.

Pauline Désogère1, Luis F Tapias2, Lida P Hariri3,4, Nicholas J Rotile1, Tyson A Rietz1, Clemens K Probst3, Francesco Blasi1, Helen Day1, Mari Mino-Kenudson4, Paul Weinreb5, Shelia M Violette5, Bryan C Fuchs6, Andrew M Tager3, Michael Lanuti7, Peter Caravan8.   

Abstract

Pulmonary fibrosis is scarring of the lungs that can arise from radiation injury, drug toxicity, environmental or genetic causes, and for unknown reasons [idiopathic pulmonary fibrosis (IPF)]. Overexpression of collagen is a hallmark of organ fibrosis. We describe a peptide-based positron emission tomography (PET) probe (68Ga-CBP8) that targets collagen type I. We evaluated 68Ga-CBP8 in vivo in the bleomycin-induced mouse model of pulmonary fibrosis. 68Ga-CBP8 showed high specificity for pulmonary fibrosis and high target/background ratios in diseased animals. The lung PET signal and lung 68Ga-CBP8 uptake (quantified ex vivo) correlated linearly (r2 = 0.80) with the amount of lung collagen in mice with fibrosis. We further demonstrated that the 68Ga-CBP8 probe could be used to monitor response to treatment in a second mouse model of pulmonary fibrosis associated with vascular leak. Ex vivo analysis of lung tissue from patients with IPF supported the animal findings. These studies indicate that 68Ga-CBP8 is a promising candidate for noninvasive imaging of human pulmonary fibrosis.
Copyright © 2017, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28381537      PMCID: PMC5568793          DOI: 10.1126/scitranslmed.aaf4696

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  48 in total

1.  Liquid chromatographic determination of hydroxyproline in tissue samples.

Authors:  Paul R Hutson; Mark E Crawford; Ronald L Sorkness
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

2.  In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011.

Authors:  John P Hutchinson; Andrew W Fogarty; Tricia M McKeever; Richard B Hubbard
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

Review 3.  Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings.

Authors:  Carolina Althoff Souza; Nestor L Müller; Julia Flint; Joanne L Wright; Andrew Churg
Journal:  AJR Am J Roentgenol       Date:  2005-12       Impact factor: 3.959

4.  The αvβ1 integrin plays a critical in vivo role in tissue fibrosis.

Authors:  Nilgun I Reed; Hyunil Jo; Chun Chen; Kazuyuki Tsujino; Thomas D Arnold; William F DeGrado; Dean Sheppard
Journal:  Sci Transl Med       Date:  2015-05-20       Impact factor: 17.956

5.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Clemens Kratochwil; Martina Benesova; Matthias Eder; Oliver C Neels; Michael Eisenhut; Wolfgang Kübler; Tim Holland-Letz; Frederik L Giesel; Walter Mier; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

6.  Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.

Authors:  Rachida Lebtahi; Severine Moreau; Sylvain Marchand-Adam; Marie-Pierre Debray; Michel Brauner; Paul Soler; Joëlle Marchal; Olivier Raguin; Anne Gruaz-Guyon; Jean-Claude Reubi; Dominique Le Guludec; Bruno Crestani
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

7.  Molecular MRI of collagen to diagnose and stage liver fibrosis.

Authors:  Bryan C Fuchs; Huifang Wang; Yan Yang; Lan Wei; Miloslav Polasek; Daniel T Schühle; Gregory Y Lauwers; Ashfaq Parkar; Anthony J Sinskey; Kenneth K Tanabe; Peter Caravan
Journal:  J Hepatol       Date:  2013-07-06       Impact factor: 25.083

Review 8.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

9.  Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation.

Authors:  Gerald S Horan; Susan Wood; Victor Ona; Dan Jun Li; Matvey E Lukashev; Paul H Weinreb; Kenneth J Simon; Kyungmin Hahm; Normand E Allaire; Nicola J Rinaldi; Jaya Goyal; Carol A Feghali-Bostwick; Eric L Matteson; Carl O'Hara; Robert Lafyatis; Gerald S Davis; Xiaozhu Huang; Dean Sheppard; Shelia M Violette
Journal:  Am J Respir Crit Care Med       Date:  2007-10-04       Impact factor: 21.405

10.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

View more
  37 in total

1.  Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis.

Authors:  Pauline Désogère; Luis F Tapias; Tyson A Rietz; Nicholas Rotile; Francesco Blasi; Helen Day; Justin Elliott; Bryan C Fuchs; Michael Lanuti; Peter Caravan
Journal:  J Nucl Med       Date:  2017-06-13       Impact factor: 10.057

2.  Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies.

Authors:  Sydney B Montesi; David Izquierdo-Garcia; Pauline Désogère; Eric Abston; Lloyd L Liang; Subba Digumarthy; Ravi Seethamraju; Michael Lanuti; Peter Caravan; Ciprian Catana
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

3.  Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis.

Authors:  Qinxue Sun; Maike Baues; Barbara M Klinkhammer; Josef Ehling; Sonja Djudjaj; Natascha I Drude; Christoph Daniel; Kerstin Amann; Rafael Kramann; Hyojin Kim; Julio Saez-Rodriguez; Ralf Weiskirchen; David C Onthank; Rene M Botnar; Fabian Kiessling; Jürgen Floege; Twan Lammers; Peter Boor
Journal:  Sci Transl Med       Date:  2019-04-03       Impact factor: 17.956

Review 4.  Matrix biomechanics and dynamics in pulmonary fibrosis.

Authors:  Andrew J Haak; Qi Tan; Daniel J Tschumperlin
Journal:  Matrix Biol       Date:  2017-12-21       Impact factor: 11.583

Review 5.  Novel Imaging Approaches in Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Sydney B Montesi; Peter Caravan
Journal:  Curr Rheumatol Rep       Date:  2019-04-25       Impact factor: 4.592

Review 6.  Update in Interstitial Lung Disease 2019.

Authors:  Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

Review 7.  Mapping COVID-19 functional sequelae: the perspective of nuclear medicine.

Authors:  Simone Cristina Soares Brandão; Júlia de Oliveira Xavier Ramos; Gustavo Freitas Alves de Arruda; Emmanuelle Tenório Albuquerque Madruga Godoi; Lara Cristiane Terra Ferreira Carreira; Rafael Willain Lopes; Gabriel Blacher Grossman; Ronaldo de Souza Leão Lima
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 8.  Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques.

Authors:  Kai Jiang; Christopher M Ferguson; Lilach O Lerman
Journal:  Transl Res       Date:  2019-04-22       Impact factor: 7.012

Review 9.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 10.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.